Physician profile
Daniel C Souphis
NPI 1225004252
$1,262.11
in general payments reported to CMS, 2019-2025
20 companies · $93.07 in 2025
The $93.07 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $204 · 2021: $173 · 2022: $46.05 · 2023: $97.10 · 2024: $236 · 2025: $93.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $231.60 | 2019-2024 | |
| Abbvie INC. | $208.64 | 2019-2025 | Qulipta, Vraylar |
| Astellas Pharma US INC | $122.44 | 2019-2021 | |
| Lilly USA, LLC | $107.97 | 2019-2024 | Jardiance, Zepbound |
| Acadia Pharmaceuticals INC | $92.63 | 2021-2025 | Nuplazid |
| Glaxosmithkline, LLC. | $62.97 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $57.29 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.26 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.61 | 2021-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $51.74 | 2019-2023 | Spravato |
| Allergan, INC. | $40.30 | 2019-2020 | |
| Pfizer INC. | $39.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.56 | 2019-2021 | |
| Amarin Pharma, INC. | $16.89 | 2019 | |
| Exact Sciences Corporation | $16.05 | 2024 | Cologuard Collection Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.69 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.64 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.13 | 2024 | Quviviq |
| Boston Scientific Corporation | $12.62 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Souphis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.